Company intelligence / Profile preview

Atherotech Diagnostics Lab

United States

Ownership: Private
Development stage: Other

Overview

Atherotech was a clinical reference laboratory specializing in cardiometabolic diagnostic testing that ceased operations in 2016. The company's proprietary VAP+ (Vertical Auto Profile) technology used density gradient ultracentrifugation to directly measure cholesterol content and lipid subclasses, providing more accurate cardiovascular disease risk identification than traditional cholesterol tests. They expanded to genetic testing and processed millions of tests annually from their central laboratory facilities.

Therapeutic areas: Cardiovascular
Modalities: Diagnostic test
Industry: Molecular Diagnostics

Partnerships

Corgenix Medical Corp.

Beyond the preview

Go deeper on Atherotech Diagnostics Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atherotech Diagnostics Lab.

Explore the full profile